Ophthalmic Formulations Market: 5-Year Shift to Innovation

The ophthalmic formulations market spent the last five years trading scale for innovation. China’s annual ophthalmology drug spend stayed above RMB 20 billion while the global market moved past USD 40 billion. What changed the game was not volume but what got sold: anti-VEGF biologics for retinal disease and atropine drops for childhood myopia. Aging eyes, screen time, and sharper consumer awareness keep pulling demand upward.

Why the ophthalmic formulations market matters now

The eye is a precise instrument, and that precision is the whole problem for drug developers. The blood-ocular barrier, split into the blood-aqueous and blood-retinal barriers, blocks medicine taken elsewhere in the body from reaching the eye in useful amounts. That is why ophthalmic treatment leans on local delivery: drops, ointments, intravitreal injections, and implants.

Five years ago this corner of pharma looked like a slow, mature segment. It does not look that way now. Aging and screen-heavy living stacked up to release steady demand, while anti-VEGF biologics rewrote retinal care and myopia-control and dry-eye products opened consumer-facing segments with real money behind them. China did not just grow faster than the global average. It shipped homegrown innovation that broke import monopolies, and that is the story worth telling.

Market size: China and the world

China’s ophthalmology drug spend held up well across the five-year window. The exact figure depends on who is counting, but the direction never changes.

Year	China ophthalmic drug spend	Note
2021	about RMB 20.3 billion	baseline year
2023	about RMB 28.8 billion	up 16.4 percent year on year
2025	about RMB 23.6 billion	up 3.87 percent year on year

Some industry estimates put China’s 2025 ophthalmic drug market closer to RMB 44 billion, with a projection of RMB 108 billion to RMB 117 billion by 2030. The gap comes from coverage: prescription only versus all outpatient drugs, and hospital terminal versus full retail. Pick a research house and you get a different number, but the arrow points the same way each time.

The global market is larger and steadier. One research track put 2025 global ophthalmic drug spend near USD 41.4 billion, heading to roughly USD 79.4 billion by 2033. Another estimated 2024 global spend at about USD 40.5 billion, expanding at a compound annual rate near 8.45 percent through 2032. Whichever lens you use, the market is climbing.

Regionally, North America holds about 38 percent of the global share on the strength of a mature retinal-care system and fast innovation approvals. Asia-Pacific, anchored by China, Japan, and South Korea, accounts for roughly 35 percent and grows faster than the industry average. That makes it the biggest source of new demand anywhere.

Three forces driving demand

Three things pulled this market up, and none of them is going away soon.

Aging builds a rigid base

Aging is the deepest engine here. By the end of 2023, people aged 60 and over made up about 19.8 percent of China’s population, with those 65 and over at 14.9 percent. Age-related macular degeneration, diabetic retinopathy, cataract, and glaucoma all rise sharply with age. These are chronic, progressive diseases that need long-term or lifelong medication, so they build a fixed base of repeat prescriptions. More than 500 million people live with diabetes worldwide, and diabetic macular edema has become a leading cause of blindness, which only enlarges the retinal-disease treatment pool.

Screens raise the eye burden

Modern life is reshaping the epidemiology of eye disease in a way we can measure. In China, average weekly internet time tops 30 hours, and phones, laptops, and tablets pushed up the rates of dry eye, eye fatigue, and allergic conjunctivitis. National health surveys count more than 700 million myopia patients, with a childhood and teen myopia rate near 52.7 percent, the highest in the world. That myopia crisis fueled a large market for low-concentration atropine drops and pulled demand across every age group, from pediatric myopia management to adult eye-fatigue relief.

Awareness and policy add tailwinds

Rising eye-health awareness moved consumers from “treat only when sick” to “manage preventively,” and that directly grew over-the-counter and eye-care rinse markets. On the policy side, dynamic reimbursement list updates gave clinically valuable innovation faster market access. Centralized procurement temporarily compressed margins on some generics but pushed the industry toward higher barriers and better products over time. Greater public health investment also lifted access to eye care.

Anti-VEGF biologics: the core growth engine

Anti-VEGF drugs, short for anti-vascular endothelial growth factor, are the clearest growth pole of the past five years. They treat wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, the blinding retinal diseases. The global anti-VEGF ophthalmic market reached about USD 16.9 billion in 2024.

In China the race is intense. Conbercept, a domestically developed anti-VEGF injection sold as Lumitin, has delivered more than 2.5 million injections since its 2014 launch. In 2024 its sales landed between RMB 2.27 billion and RMB 2.34 billion, holding the top domestic spot with a 44.4 percent revenue share and a 47.5 percent volume share. After all its indications entered the reimbursement list in 2022, its price sat 30 to 40 percent below imported rivals, which sped adoption.

Imported products stayed competitive. Aflibercept, from Regeneron and Bayer and sold as Eylea, posted RMB 923 million in China sales in 2024 and, in the first three quarters of 2025, reached RMB 765 million to narrowly pass conbercept’s RMB 753 million. Ranibizumab, from Novartis and sold as Lucentis, fell from a 2023 peak of RMB 1.729 billion to RMB 1.349 billion in 2024. Faricimab, from Roche and sold as Vabysmo, is the first bispecific antibody in ophthalmology, hitting both VEGF-A and Ang-2. Its 2024 global sales hit USD 4.67 billion, up 68 percent, while in China it grew more than tenfold to RMB 391 million.

Biosimilars are now pressing on the originators. Qilu’s aflibercept biosimilar won approval in December 2023, and products from Luye, Ocumension, and Bio-Thera followed in November 2025, adding price pressure on the established brands.

Myopia-control drops: a new blue ocean

Low-concentration atropine sulfate eye drops became the most talked-about ophthalmic launch of the five years. A 0.01 percent formulation developed by Sinqi and sold as Miropine won approval in 2024 as the first prescription drug in China to slow childhood myopia progression. The effect on the maker was dramatic: Sinqi’s eye-drop revenue hit RMB 1.366 billion in 2024, up 106.08 percent, climbing past 70 percent of total revenue. For the full year 2025 the company booked RMB 2.473 billion in revenue with RMB 696 million in net profit.

The addressable space is large. Estimates put China’s low-concentration atropine market above RMB 9 billion by 2030. Zhaoke, Hengrui, and Sapio, among others, have atropine programs in clinical stages. Presbyopia treatment, led by pilocarpine hydrochloride drops, is seen as the next heavyweight track, with a 2030 space projected above RMB 10 billion.

Anti-inflammatory and anti-infective: the stable base

In the traditional segment, anti-inflammatory and anti-infective drugs form the floor of the market. Pranoprofen eye drops led Chinese anti-inflammatory products in 2024 with more than RMB 700 million in sales and about a 45 percent share. Levofloxacin and tobramycin drops together passed RMB 1 billion across all terminals in 2025. Sodium hyaluronate drops, the standard dry-eye treatment, reached RMB 2.123 billion in public hospitals and city pharmacies in 2025.

Centralized procurement left a mark here. Sodium hyaluronate entered the fourth national procurement round in 2021, and its terminal sales dropped more than 30 percent in the first half of 2022. In the first half of 2024, ophthalmic drug sales across public hospitals fell 6.21 percent year on year, with procurement-driven price pressure a major factor.

Dosage forms: drops lead, injections surge

Eye drops remain the dominant form, and the eye drop market in China reached about RMB 16.599 billion in 2025, up 6.12 percent. At Sinqi, drops already exceed 70 percent of revenue. Ophthalmic injectables, above all anti-VEGF intravitreal shots, are the fastest-growing form because they are irreplaceable in retinal care. Implants and sustained-release microspheres are beginning to land and could further reshape the form mix.

The competitive map: foreign leaders, local challengers

The field splits cleanly. Foreign firms lead on innovation and high-end products, while domestic firms compete in tiers. Novartis, Alcon, and Santen hold strong positions in premium prescription drugs, especially anti-VEGF and novel ocular-surface products, with Novartis ranking first among groups in public hospital terminal sales in the first half of 2024.

Domestic players are moving from generic to innovative fast. Kanghong is the benchmark: 2024 revenue of RMB 4.453 billion, up 12.51 percent, with RMB 1.191 billion in net profit. Its conbercept broke the import monopoly in retinal care and became China’s first original Class I biologic to earn a WHO international nonproprietary name. Sinqi’s atropine surge took 2024 revenue to RMB 1.943 billion, up 32.42 percent. Ocumension reached RMB 417 million in 2024 revenue, up 69.4 percent, with ophthalmic product sales up 87.8 percent.

Consistency evaluation and procurement reset the entry bar. Twenty-four ophthalmic varieties have passed consistency evaluation, with sodium hyaluronate at 41 companies and moxifloxacin hydrochloride at 40. By variety count, Sinqi, Qilu, and Zhongshan Wanhan lead. Procurement cut short-term prices but accelerated consolidation toward firms with real R&D and scale.

Where the market goes next

Bispecific and multi-target biologics raise the bar

Faricimab proved the clinical and commercial value of dual targeting. Domestic developers are following: a VEGF-A and Ang-2 bispecific from Koscius won clinical approval in 2025. Dual and multi-target designs should lift efficacy while stretching the dosing interval and improving adherence, which makes them the mainstream direction in retinal care.

Gene therapy crosses from concept to clinic

Gene therapy is among the most disruptive fronts in ophthalmology. The eye’s immune privilege and enclosed anatomy make it an ideal target organ. Kanghong’s two AAV gene therapies, KH631 in Phase II and KH658 in Phase I, target wet AMD through suprachoroidal injection for long-term effect from a single dose. Several ocular gene therapies are in late-stage trials worldwide. Positive data could rewrite the treatment model for inherited and degenerative eye disease within five to ten years.

Novel delivery systems solve the bioavailability problem

Conventional drops have very low bioavailability because medicine must clear the corneal barrier, tear washout, and aqueous circulation. Sustained-release implants, nanomicelles, and preservative-free long-acting drops are chipping at that wall. These tools span materials science and pharmacokinetics, carry high barriers, and promise strong clinical and commercial returns once solved.

Artificial intelligence speeds research and individualized care

AI is moving deeper into ophthalmic drug work. Multimodal biomarker monitoring can support individualized treatment plans. Folded into the innovation pipeline, AI can lift efficiency and cut cost across target discovery, compound screening, and trial design, shortening the long R&D cycle.

Consumer medicine and prescription blur

Myopia control, dry-eye management, and eye-fatigue relief carry consumer-medicine traits and are growing fast. Atropine’s commercial win proved the potential. As awareness rises and spending upgrades, products that treat and care at once should keep expanding and become a new growth engine.

Bottom line

The past five years show a market moving from scale to innovation, from import reliance to domestic breakthrough, and from traditional forms to technical variety. China held above RMB 20 billion in annual spend while the world crossed USD 40 billion, lifted by aging, screens, and awareness together. Anti-VEGF moved from single to dual targets, myopia control broke from zero to one, and gene therapy moved from lab to clinic. China’s ophthalmic market could pass RMB 100 billion by 2030. The winners will be the firms that break technical barriers and meet real unmet clinical need.

FAQ

How big is the ophthalmic formulations market today?

The global ophthalmic drug market reached roughly USD 41.4 billion in 2025 and is projected near USD 79.4 billion by 2033. China’s spend held above RMB 20 billion a year through 2025, with some estimates close to RMB 44 billion and a 2030 range of RMB 108 billion to RMB 117 billion. Differences come from statistical caliber, but every track shows steady expansion.

What is driving growth in the ophthalmic drugs market?

Three forces drive demand. Population aging raises chronic retinal disease that needs lifelong medicine. Digital lifestyles push up myopia, dry eye, and eye fatigue across all ages. Rising eye-health awareness and supportive reimbursement and procurement policy move consumers from treatment to prevention, widening the over-the-counter and care segments.

What are anti-VEGF drugs used for?

Anti-VEGF drugs treat blinding retinal diseases by blocking vascular endothelial growth factor, a protein that drives abnormal vessel leakage and growth. They are used for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The global anti-VEGF ophthalmic market reached about USD 16.9 billion in 2024 and remains the field’s core growth engine.

How does conbercept compare with aflibercept in China?

Conbercept, sold as Lumitin, led China’s anti-VEGF market with a 44.4 percent revenue share and 47.5 percent volume share in 2024, on sales of RMB 2.27 billion to RMB 2.34 billion. Aflibercept, sold as Eylea, posted RMB 923 million in 2024 and, in early 2025, briefly passed conbercept in quarterly sales. Conbercept sits 30 to 40 percent below import pricing after reimbursement entry.

Are atropine eye drops effective for childhood myopia?

A 0.01 percent low-concentration atropine sulfate drop, sold as Miropine, won approval in 2024 as China’s first prescription drug to slow childhood myopia progression. Its maker’s eye-drop revenue more than doubled that year. The China market for this drop is projected above RMB 9 billion by 2030, though use should follow a clinician’s plan rather than self-treatment.

What is the outlook for the ophthalmic market through 2030?

China’s ophthalmic market could pass RMB 100 billion by 2030 under current trends, lifted by aging, screens, and awareness. Globally, spend is set to near USD 79.4 billion by 2033. Growth centers on anti-VEGF biologics, myopia-control drops, gene therapy, and novel delivery, with domestic innovation closing the gap on imports.

Why are biosimilars changing the anti-VEGF landscape?

Biosimilars lower the price of established anti-VEGF brands and widen patient access. Qilu’s aflibercept biosimilar won approval in late 2023, and Luye, Ocumension, and Bio-Thera followed in 2025. As more copycat biologics reach the market, originator price systems face pressure, accelerating adoption but squeezing margins for first movers.

What role does gene therapy play in ophthalmology?

The eye’s immune privilege and closed structure make it an ideal gene-therapy target. AAV therapies such as KH631 and KH658 aim at wet AMD through suprachoroidal injection for long-term effect from one dose. Several ocular gene therapies are in late trials worldwide, and positive data could reshape treatment for inherited and degenerative eye disease within a decade.

How are new drug delivery systems improving eye treatments?

Conventional drops lose most medicine to the corneal barrier, tear washout, and aqueous flow. Sustained-release implants, nanomicelles, and preservative-free long-acting drops raise bioavailability and cut dosing frequency. These systems cross materials science and pharmacokinetics, carry high R&D barriers, and offer strong clinical and commercial upside once solved.

How is artificial intelligence used in ophthalmic drug development?

AI supports multimodal biomarker monitoring that can guide individualized treatment plans. Inside the pipeline, it aids target discovery, compound screening, and trial design, lifting efficiency and lowering cost to shorten long development cycles. Its role grows across the full chain from discovery to clinic as data and models mature.